Skip to main content
Top
Published in: Cancer Causes & Control 2/2009

01-03-2009 | Original Paper

Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case–control study

Authors: Maria Dalamaga, Konstantinos Karmaniolas, Anna Panagiotou, Alex Hsi, John Chamberland, Cleanthi Dimas, Antigoni Lekka, Christos S. Mantzoros

Published in: Cancer Causes & Control | Issue 2/2009

Login to get access

Abstract

Accumulating evidence supports a role for obesity in the etiology of multiple myeloma (MM). The distinct possibility exists that obesity may be linked to MM through altered adipokine secretion and circulating levels, one of which, adiponectin, has a protective role in several malignancies, including leukemia. In this case–control study, we investigated the role of serum adiponectin, resistin, and leptin levels in the etiopathogenesis of MM and we explored their association with several established prognostic factors. Seventy three patients with incident, histologically confirmed MM and 73 controls matched on gender and age were studied between 2001 and 2007, and blood samples were collected. Serum adiponectin, leptin, resistin, as well as MM prognostic parameters were determined. Statistical analysis of the data was performed using univariate and multivariate analyses. Lower serum adiponectin and resistin levels were associated with higher risk of MM by bivariate analysis and after adjusting for age, gender, BMI, and serum levels of leptin (p < 0.0001). Adiponectin may have a protective role in MM, whereas leptin was not associated with risk for MM at a comparable level of significance and resistin levels may be decreased via a compensatory mechanism. Further studies are needed to confirm these associations and to explore the mechanisms underlying adiponectin’s role in MM and plasma cell dyscrasias.
Literature
1.
go back to reference Foerster J, Paraskevas F (1998) Multiple myeloma. In: Lee GR, Foerster J, Luken J, Paraskevas F, Greer JP, Rodgers GM, Wintrobe MM (eds) Wintrobe’s clinical hematology, vol 2. Lippincott Williams & Wilkins, Baltimore, pp 2631–2655 Foerster J, Paraskevas F (1998) Multiple myeloma. In: Lee GR, Foerster J, Luken J, Paraskevas F, Greer JP, Rodgers GM, Wintrobe MM (eds) Wintrobe’s clinical hematology, vol 2. Lippincott Williams & Wilkins, Baltimore, pp 2631–2655
3.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef
4.
go back to reference Lewis DR, Pottern LM, Brown LM, Silverman DT, Hayes RB, Schoenberg JB, Greenberg RS, Swanson GM, Schwartz AG, Liff JM (1994) Multiple myeloma among blacks and whites in the United States: the role of chronic antigenic stimulation. Cancer Causes Control 5:529–539. doi:10.1007/BF01831381 PubMedCrossRef Lewis DR, Pottern LM, Brown LM, Silverman DT, Hayes RB, Schoenberg JB, Greenberg RS, Swanson GM, Schwartz AG, Liff JM (1994) Multiple myeloma among blacks and whites in the United States: the role of chronic antigenic stimulation. Cancer Causes Control 5:529–539. doi:10.​1007/​BF01831381 PubMedCrossRef
7.
go back to reference Bourguet CC, Logue EE (1993) Antigenic stimulation and multiple myeloma. A prospective study. Cancer 72:2148–2154. doi :10.1002/1097-0142(19931001)72:7<2148::AID-CNCR2820720714>3.0.CO;2-QPubMedCrossRef Bourguet CC, Logue EE (1993) Antigenic stimulation and multiple myeloma. A prospective study. Cancer 72:2148–2154. doi :10.1002/1097-0142(19931001)72:7<2148::AID-CNCR2820720714>3.0.CO;2-QPubMedCrossRef
12.
go back to reference Chan JL, Moschos SJ, Bullen J, Heist K, Li X, Kim YB, Kahn BB, Mantzoros CS (2005) Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-alpha receptor levels in humans with relative leptin deficiency. J Clin Endocrinol Metab 90:1625–1631. doi:10.1210/jc.2004-1823 PubMedCrossRef Chan JL, Moschos SJ, Bullen J, Heist K, Li X, Kim YB, Kahn BB, Mantzoros CS (2005) Recombinant methionyl human leptin administration activates signal transducer and activator of transcription 3 signaling in peripheral blood mononuclear cells in vivo and regulates soluble tumor necrosis factor-alpha receptor levels in humans with relative leptin deficiency. J Clin Endocrinol Metab 90:1625–1631. doi:10.​1210/​jc.​2004-1823 PubMedCrossRef
13.
go back to reference Matarese G, Moschos S, Mantzoros CS (2005) Leptin in immunology. J Immunol 174:3137–3142PubMed Matarese G, Moschos S, Mantzoros CS (2005) Leptin in immunology. J Immunol 174:3137–3142PubMed
14.
16.
go back to reference Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D (2004) Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89:1102–1107. doi:10.1210/jc.2003-031804 PubMedCrossRef Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D (2004) Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89:1102–1107. doi:10.​1210/​jc.​2003-031804 PubMedCrossRef
17.
go back to reference Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, La Vecchia C (2004) Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 89:1160–1163. doi:10.1210/jc.2003-031716 PubMedCrossRef Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, La Vecchia C (2004) Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 89:1160–1163. doi:10.​1210/​jc.​2003-031716 PubMedCrossRef
20.
go back to reference Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS (2007) Low adiponectin levels are associated with renal cell carcinoma: a case–control study. Int J Cancer 120:1573–1578. doi:10.1002/ijc.22526 PubMedCrossRef Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS (2007) Low adiponectin levels are associated with renal cell carcinoma: a case–control study. Int J Cancer 120:1573–1578. doi:10.​1002/​ijc.​22526 PubMedCrossRef
21.
go back to reference Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS (2005) Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97:1688–1694PubMedCrossRef Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS (2005) Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97:1688–1694PubMedCrossRef
24.
go back to reference Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS (2003) Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 88:4848–4856. doi:10.1210/jc.2003-030519 PubMedCrossRef Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS (2003) Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 88:4848–4856. doi:10.​1210/​jc.​2003-030519 PubMedCrossRef
25.
go back to reference Pamuk GE, Demir M, Harmandar F, Yesil Y, Turgut B, Vural O (2006) Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristics. Exp Oncol 28:241–244PubMed Pamuk GE, Demir M, Harmandar F, Yesil Y, Turgut B, Vural O (2006) Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristics. Exp Oncol 28:241–244PubMed
26.
go back to reference Alexandrakis MG, Passam FH, Sfiridaki A, Pappa CA, Moschandrea JA, Kandidakis E, Tsirakis G, Kyriakou DS (2004) Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines. Int J Biol Markers 19:52–57PubMed Alexandrakis MG, Passam FH, Sfiridaki A, Pappa CA, Moschandrea JA, Kandidakis E, Tsirakis G, Kyriakou DS (2004) Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines. Int J Biol Markers 19:52–57PubMed
27.
go back to reference Durie BGM (1986) Staging and kinetics of multiple myeloma. Semin Oncol 13:300–309PubMed Durie BGM (1986) Staging and kinetics of multiple myeloma. Semin Oncol 13:300–309PubMed
28.
go back to reference Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842–854. doi :10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-UPubMedCrossRef Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842–854. doi :10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-UPubMedCrossRef
29.
go back to reference SAS/STAT User’s Guide (1989) NC, Cary. Ref Type: Computer Program SAS/STAT User’s Guide (1989) NC, Cary. Ref Type: Computer Program
31.
go back to reference Ajuwon KM, Spurlock ME (2005) Adiponectin inhibits LPS-induced NF-kB activation and IL-6 production and increases PPARγ2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 288:1220–1225. doi:10.1152/ajpregu.00397.2004 Ajuwon KM, Spurlock ME (2005) Adiponectin inhibits LPS-induced NF-kB activation and IL-6 production and increases PPARγ2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 288:1220–1225. doi:10.​1152/​ajpregu.​00397.​2004
34.
go back to reference Chan JL, Matarese G, Shetty GK, Raciti P, Kelesidis I, Aufiero D, De Rosa V, Perna F, Fontana S, Mantzoros CS (2006) Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans. Proc Natl Acad Sci USA 103:8481–8486. doi:10.1073/pnas.0505429103 PubMedCrossRef Chan JL, Matarese G, Shetty GK, Raciti P, Kelesidis I, Aufiero D, De Rosa V, Perna F, Fontana S, Mantzoros CS (2006) Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans. Proc Natl Acad Sci USA 103:8481–8486. doi:10.​1073/​pnas.​0505429103 PubMedCrossRef
35.
go back to reference Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312. doi:10.1038/35053000 PubMedCrossRef Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312. doi:10.​1038/​35053000 PubMedCrossRef
36.
go back to reference Rajala MW, Obici S, Scherer PE, Rossetti L (2003) Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 111:225–230PubMed Rajala MW, Obici S, Scherer PE, Rossetti L (2003) Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 111:225–230PubMed
37.
go back to reference Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K, Nagai R (2004) Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 314:415–419. doi:10.1016/j.bbrc.2003.12.104 PubMedCrossRef Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K, Nagai R (2004) Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 314:415–419. doi:10.​1016/​j.​bbrc.​2003.​12.​104 PubMedCrossRef
38.
go back to reference Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O’Rahilly S (2001) Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50:2199–2202. doi:10.2337/diabetes.50.10.2199 PubMedCrossRef Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O’Rahilly S (2001) Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50:2199–2202. doi:10.​2337/​diabetes.​50.​10.​2199 PubMedCrossRef
Metadata
Title
Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case–control study
Authors
Maria Dalamaga
Konstantinos Karmaniolas
Anna Panagiotou
Alex Hsi
John Chamberland
Cleanthi Dimas
Antigoni Lekka
Christos S. Mantzoros
Publication date
01-03-2009
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 2/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9233-7

Other articles of this Issue 2/2009

Cancer Causes & Control 2/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine